(Q34405313)

2 August 2017

1 reference

title

Fluvoxamine as an adjunctive agent in schizophrenia (English)

1 reference

2 August 2017

Fluvoxamine as an Adjunctive Agent in Schizophrenia (English)

0 references

1 reference

1 reference

Silver H

1

1 reference

2 August 2017

Henry Silver

series ordinal

1

0 references

publication date

1 January 2001

1 reference

CNS Neuroscience & Therapeutics

2 August 2017

7 June 2006

0 references

published in

1 reference

2 August 2017

7

1 reference

2 August 2017

3

1 reference

2 August 2017

283-304

1 reference

Clozapine potently stimulates mesocortical dopamine neurons.

2 August 2017

1 reference

12 December 2020

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

1 reference

12 December 2020

Fluvoxamine-methadone interaction.

1 reference

12 December 2020

Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.

1 reference

12 December 2020

Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience

1 reference

12 December 2020

Distinguishing change in primary and secondary negative symptoms

1 reference

12 December 2020

In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine

1 reference

12 December 2020

Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial

1 reference

12 December 2020

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

12 December 2020

Elevated plasma levels of clozapine after concomitant use of fluvoxamine

1 reference

12 December 2020

Depressive symptoms in schizophrenia

1 reference

12 December 2020

Obsessive-compulsive disorder in patients with first-episode schizophrenia.

1 reference

12 December 2020

Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data.

1 reference

12 December 2020

Fluvoxamine-Clozapine Drug Interaction: Inhibition In Vitro of Five Cytochrome P450 Isoforms Involved in Clozapine Metabolism

1 reference

12 December 2020

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

1 reference

12 December 2020

Increased bioavailability of oral melatonin after fluvoxamine coadministration.

1 reference

12 December 2020

Pharmacokinetics of selective serotonin reuptake inhibitors

1 reference

12 December 2020

MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine

1 reference

12 December 2020

Paroxetine binding in aggressive schizophrenic patients

1 reference

12 December 2020

Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight

1 reference

12 December 2020

A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling

1 reference

12 December 2020

Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics

1 reference

12 December 2020

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

1 reference

12 December 2020

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

1 reference

12 December 2020

1 reference

12 December 2020

Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment

1 reference

12 December 2020

Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients

1 reference

12 December 2020

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

1 reference

12 December 2020

Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes

1 reference

12 December 2020

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders

1 reference

12 December 2020

Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study

1 reference

12 December 2020

Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin

1 reference

12 December 2020

The importance of serotonin-dopamine interactions in the action of clozapine

1 reference

12 December 2020

Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects

1 reference

12 December 2020

Negative symptomatology in schizophrenic outpatients

1 reference

12 December 2020

Human cytochromes P450: problems and prospects

1 reference

12 December 2020

Testing systems for assessment of negative symptoms in schizophrenia

1 reference

12 December 2020

Reliability and validity of a depression rating scale for schizophrenics

1 reference

12 December 2020

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

1 reference

12 December 2020

Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients

1 reference

12 December 2020

The use of antidepressants for negative symptoms in a subset of schizophrenic patients

1 reference

12 December 2020

Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy

1 reference

12 December 2020

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

1 reference

12 December 2020

Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats

1 reference

12 December 2020

Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers

1 reference

12 December 2020

A depression rating scale for schizophrenics

1 reference

12 December 2020

Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia

1 reference

12 December 2020

Positive and negative symptoms in schizophrenia. A critical reappraisal

1 reference

12 December 2020

The positive:negative dichotomy in schizophrenia.

1 reference

12 December 2020

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

1 reference

12 December 2020

Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness

1 reference

12 December 2020

The nature and prevalence of depression in chronic schizophrenic in-patients

1 reference

12 December 2020

Dysphoric and depressive symptoms in chronic schizophrenia

1 reference

12 December 2020

The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia

1 reference

12 December 2020

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

1 reference

12 December 2020

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

12 December 2020

Negative and depressive symptoms in schizophrenia

1 reference

12 December 2020

Treatment of negative symptoms

1 reference

12 December 2020

Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.

1 reference

12 December 2020

'Akinetic Depression' in Schizophrenia

1 reference

12 December 2020

Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor

1 reference

12 December 2020

Postpsychotic depression and negative symptoms: an investigation of syndromal overlap

1 reference

12 December 2020

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

12 December 2020

The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine

1 reference

12 December 2020

Fluvoxamine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Reliability and validity of the positive and negative syndrome scale for schizophrenics

1 reference

12 December 2020

Schizophrenia: lifetime co-morbidity in a community sample.

1 reference

12 December 2020

Rating scales in research: the case of negative symptoms

1 reference

12 December 2020

Implications of normal brain development for the pathogenesis of schizophrenia

1 reference

12 December 2020

A Negative Symptom Rating Scale

1 reference

12 December 2020

The prognostic significance of obsessive-compulsive symptoms in schizophrenia

1 reference

12 December 2020

"Negative symptoms": conceptual and methodological problems

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

The classification of depressive illness

1 reference

12 December 2020

Fluvoxamine and chlorimipramine in endogenous depression

1 reference

12 December 2020

Review of the animal pharmacology and pharmacokinetics of fluvoxamine

1 reference

12 December 2020

Fluvoxamine maleate: metabolism in man

1 reference

12 December 2020

Costs and benefits of two doses of fluphenazine

1 reference

12 December 2020

Negative and positive symptoms in schizophrenia and depression: a followup

1 reference

12 December 2020

Negative v positive schizophrenia. Definition and validation.

1 reference

12 December 2020

Positive and negative schizophrenic symptoms and the role of dopamine

1 reference

12 December 2020

The negative component in schizophrenia

1 reference

12 December 2020

Psychotic symptoms in schizophrenics during chronic fluvoxamine treatment. A report of two cases

1 reference

12 December 2020

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

1 reference

12 December 2020

A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia

1 reference

12 December 2020

Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia

1 reference

12 December 2020

Obsessive and compulsive symptoms in chronic schizophrenia

1 reference

12 December 2020

Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats

1 reference

12 December 2020

A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change.

1 reference

12 December 2020

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

12 December 2020

Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine

1 reference

12 December 2020

Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA

1 reference

12 December 2020

Fluvoxamine augmentation for clozapine-resistant schizophrenia.

1 reference

12 December 2020

Coadministration of fluvoxamine increases serum concentrations of haloperidol

1 reference

12 December 2020

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

1 reference

12 December 2020

Fluvoxamine. A review of its safety profile in world-wide studies.

1 reference

12 December 2020

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

12 December 2020

Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications.

1 reference

12 December 2020

Endogenous serotonin stimulates striatal dopamine release in conscious rats

1 reference

12 December 2020

Toxic effects of theophylline caused by fluvoxamine

1 reference

12 December 2020

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

12 December 2020

Elevated levels of clozapine in serum after addition of fluvoxamine

1 reference

12 December 2020

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

12 December 2020

Prescription-event monitoring of 10,401 patients treated with fluvoxamine

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

12 December 2020

Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats

1 reference

12 December 2020

Fluvoxamine treatment of body dysmorphic disorder

1 reference

12 December 2020

Probable metabolic interaction between methadone and fluvoxamine in addict patients

1 reference

12 December 2020

Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

1 reference

12 December 2020

Open trial of fluvoxamine in the treatment of bulimia nervosa.

1 reference

12 December 2020

Increased trimipramine plasma levels during fluvoxamine comedication

1 reference

12 December 2020

Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients

1 reference

12 December 2020

Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage

1 reference

12 December 2020

Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration

1 reference

12 December 2020

Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

1 reference

12 December 2020

Serotonin receptors and animal models of aggressive behavior

1 reference

12 December 2020

Elevated clozapine plasma concentrations after fluvoxamine initiation

1 reference

12 December 2020

Serotonin syndrome and fluvoxamine: a case study

1 reference

12 December 2020

Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

1 reference

12 December 2020

Elevated clozapine levels after fluvoxamine initiation

1 reference

12 December 2020

Treatment of kleptomania with fluvoxamine.

1 reference

12 December 2020

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo

1 reference

12 December 2020

Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient

1 reference

12 December 2020

Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin re-uptake inhibitor

1 reference

12 December 2020

A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

1 reference

12 December 2020

Depression in schizophrenia: a comparison of three measures

1 reference

12 December 2020

A fluvoxamine-caffeine interaction study

1 reference

12 December 2020

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

12 December 2020

Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients

1 reference

12 December 2020

Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain

1 reference

12 December 2020

Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.

1 reference

12 December 2020

Overview of the pharmacokinetics of fluvoxamine

1 reference

12 December 2020

Fluvoxamine increases the clozapine serum levels significantly

1 reference

12 December 2020

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

12 December 2020

A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder

1 reference

12 December 2020

Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study

1 reference

12 December 2020

Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study

1 reference

12 December 2020

The Oral Dose-Effect Relationship for Fluvoxamine: a Fixed-Dose Comparison Against Placebo in Depressed Outpatients

1 reference

12 December 2020

In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine

1 reference

12 December 2020

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

1 reference

12 December 2020

Prefrontal function in schizophrenia: confounds and controversies

1 reference

12 December 2020

Fluoxetine augmentation of clozapine treatment in patients with schizophrenia

1 reference

12 December 2020

Fluvoxamine-clozapine dose-dependent interaction

1 reference

12 December 2020

Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports

1 reference

12 December 2020

Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.

1 reference

12 December 2020

Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia.

1 reference

12 December 2020

The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition

1 reference

12 December 2020

19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder

1 reference

12 December 2020

Fluvoxamine in the treatment of compulsive buying

1 reference

12 December 2020

Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin

1 reference

12 December 2020

Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design

1 reference

12 December 2020

Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.

1 reference

12 December 2020

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans

1 reference

12 December 2020

Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa.

1 reference

12 December 2020

Fluvoxamine treatment of trichotillomania

1 reference

12 December 2020

Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications

1 reference

12 December 2020

Fluvoxamine-induced theophylline toxicity

1 reference

12 December 2020

Buspirone augmentation of fluvoxamine in the treatment of kleptomania.

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

1 reference

12 December 2020

The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy

1 reference

12 December 2020

Pharmacologic treatment of obsessive-compulsive disorder: comparative studies

1 reference

12 December 2020

Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage

1 reference

12 December 2020

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study

1 reference

12 December 2020

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

1 reference

12 December 2020

Efficacy and safety of fluvoxamine in body dysmorphic disorder.

1 reference

12 December 2020

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.

1 reference

12 December 2020

Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.

1 reference

12 December 2020

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

1 reference

12 December 2020

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

1 reference

12 December 2020

A fatal drug interaction between clozapine and fluoxetine

1 reference

12 December 2020

Treatment of aggression in schizophrenia

1 reference

12 December 2020

Depression in people with first-episode schizophrenia

1 reference

12 December 2020

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

12 December 2020

Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial

1 reference

12 December 2020

Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial

1 reference

12 December 2020

Short-term single-blind fluvoxamine treatment of pathological gambling

1 reference

12 December 2020

Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine?

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro

1 reference

12 December 2020

10.1111/J.1527-3458.2001.TB00200.X

Identifiers

DOI

0 references

0 references

1 reference